Rivaroxaban and Cardiotoxicity - a phase IV clinical study of FDA data

Summary:

Cardiotoxicity is reported as a side effect among people who take Rivaroxaban (rivaroxaban), especially for people who are female, 20-29 old, also take Heparin, and have Synovial sarcoma.

The phase IV clinical study analyzes which people have Cardiotoxicity when taking Rivaroxaban. It is created by eHealthMe based on reports of 26,430 people who have side effects when taking Rivaroxaban from the FDA, and is updated regularly.

What is Rivaroxaban?

Rivaroxaban has active ingredients of rivaroxaban. It is often used in blood clots. eHealthMe is studying from 26,544 Rivaroxaban users. Check the latest studies of Rivaroxaban.

What is Cardiotoxicity?

Cardiotoxicity (damage to the heart muscle) is found to be associated with 384 drugs and 511 conditions by eHealthMe. Check the latest studies of Cardiotoxicity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

26,430 people reported to have side effects when taking Rivaroxaban.
Among them, 24 people (0.09%) have Cardiotoxicity.

Among these 24 people:

What is the gender of people who have Cardiotoxicity when taking Rivaroxaban? *

female: 64.71 %
male: 35.29 %

What is the age of people who have Cardiotoxicity when taking Rivaroxaban? *

What are other drugs people take besides Rivaroxaban? *

What are other side effects people have besides Cardiotoxicity? *

Cardiogenic Shock (inadequate circulation of blood): 7 people, 29.17%
Arrhythmias (irregular heartbeat): 6 people, 25.00%
Ventricular Tachycardia (rapid heartbeat that originates in one of the lower chambers (the ventricles) of the heart): 4 people, 16.67%
Torsade De Pointes (a abnormal heart rate with abnormal beating pattern): 4 people, 16.67%
Overdose: 4 people, 16.67%
Hyperthyroidism (over activity of the thyroid gland): 3 people, 12.50%
Cardiac Arrest: 3 people, 12.50%
Heart Palpitations (feelings or sensations that your heart is pounding or racing): 3 people, 12.50%
Fatigue (feeling of tiredness): 3 people, 12.50%
Stress And Anxiety: 3 people, 12.50%

What are the existing conditions these people have? *

Synovial Sarcoma (tumour of synovial membrane of joint): 7 people, 29.17%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 5 people, 20.83%
Pulmonary Embolism (blockage of the main artery of the lung): 4 people, 16.67%
Ventricular Tachycardia (rapid heartbeat that originates in one of the lower chambers (the ventricles) of the heart): 3 people, 12.50%
Torsade De Pointes (a abnormal heart rate with abnormal beating pattern): 3 people, 12.50%
Ejection Fraction (the percentage of blood that is pumped out of a filled ventricle as a result of a heartbeat): 3 people, 12.50%
Cardiac Failure: 3 people, 12.50%
Overdose: 2 people, 8.33%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 2 people, 8.33%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 2 people, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Rivaroxaban and have Cardiotoxicity?

- Check whether Cardiotoxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rivaroxaban:

Rivaroxaban (26,544 reports)

Cardiotoxicity treatments and more:

Cardiotoxicity (8,120 reports)

Browse all side effects of Rivaroxaban:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cardiotoxicity:

Cardiotoxicity (384 drugs)

Browse all the conditions that are associated with Cardiotoxicity:

Cardiotoxicity (511 conditions)

Related publications that referenced our studies

Alam, S., Illo, C., Ma, Y. T., & Punia, P. , "Gemcitabine-induced cardiotoxicity in patients receiving adjuvant chemotherapy for pancreatic cancer: a case series", Case reports in oncology, 2018 Jan .
Alam, S., Illo, C., Ma, Y. T., & Punia, P. , "Gemcitabine-induced cardiotoxicity in patients receiving adjuvant chemotherapy for pancreatic cancer: a case series", Case reports in oncology, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on rivaroxaban (the active ingredients of Rivaroxaban) and Rivaroxaban (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.